Analyst Price Targets — ABUS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2022 12:00 am | Ed Arce | H.C. Wainwright | $8.50 | $3.02 | Pulse 2.0 | Arbutus Biopharma (ABUS) Stock: $8.50 Price Target And Buy Rating |
Latest News for ABUS
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABUS.
U.S. House Trading
No House trades found for ABUS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.